CClinicalTrials.gg
Enrolling by invitationNCT07525973Updated Sep 15, 2026

The Effect of Eye Exercises in Parkinson's Disease

An interventional study of Supervised In-Center Eye Exercises in Parkinson Disease, sponsored by Pardis Specialized Wellness Institute. Enrolling by invitation at 1 site in Iran. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Pardis Specialized Wellness Institute · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Parkinson's disease is commonly associated with impaired gait, postural instability, reduced physical function, and increased concern about falling, all of which contribute substantially to disability and reduced quality of life. Exercise-based rehabilitation is increasingly recommended as a core non-pharmacological strategy for improving mobility and balance in people with Parkinson's disease. In parallel, recent clinical and neurorehabilitation research suggests that eye-movement and gaze-stabilization training may influence postural control, visuomotor integration, and movement performance in neurological disorders, including Parkinson's disease. This randomized controlled trial will evaluate whether a supervised in-center eye-exercise program can improve dynamic balance, functional mobility, gait performance, and fall-related concern in patients with Parkinson's disease.

Read the detailed description

Parkinson's disease is a progressive neurodegenerative disorder characterized not only by tremor and bradykinesia, but also by impaired gait, postural instability, reduced turning ability, slowed mobility, and increased fear of falling. These impairments are major contributors to functional limitation, reduced independence, and decreased quality of life in people with Parkinson's disease. Recent systematic reviews and network meta-analyses have demonstrated that exercise interventions can improve physical function, balance, gait performance, and mobility-related outcomes in this population. However, balance impairment and falls remain highly prevalent despite conventional rehabilitation approaches, highlighting the need for additional targeted non-pharmacological interventions.

Visual and oculomotor dysfunction are increasingly recognized as clinically relevant features of Parkinson's disease. Abnormalities in saccadic eye movements, smooth pursuit, gaze stabilization, and visuomotor control have been reported in patients with Parkinson's disease and may contribute to impaired postural control, gait dysfunction, and difficulties with movement coordination. Recent studies in neurorehabilitation and eye-movement research suggest that eye exercises and visually guided training may positively influence balance control, mobility, and motor-related performance by enhancing sensory integration and visuomotor coordination.

Emerging rehabilitation studies have reported promising effects of structured eye-movement interventions on dynamic balance, walking performance, and functional mobility in individuals with Parkinson's disease. In addition, recent advances in eye-tracking and oculomotor assessment research further support the potential therapeutic relevance of visually guided interventions in Parkinson's disease rehabilitation. Nevertheless, high-quality randomized controlled trials investigating supervised eye-exercise programs in clinical settings remain limited.

Therefore, the present study will investigate the effects of a structured supervised in-center eye-exercise program on physical function, dynamic balance, and fall-related concern in patients with Parkinson's disease. The intervention will be delivered under direct supervision in a controlled rehabilitation/clinic setting. By focusing on clinically meaningful functional outcomes, this trial aims to determine whether supervised eye exercises may represent a practical and effective adjunct rehabilitation strategy for improving mobility- and balance-related outcomes in people with Parkinson's disease.

All functional assessments will be performed at approximately the same time of day and in the participant's usual "ON" medication state, preferably 1-2 hours after antiparkinsonian medication intake, where feasible. Medication timing will be recorded at each assessment.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson disease
  • Eye exercises
  • Balance
  • Fall risk
  • Physical function
  • Functional mobility
  • Gait
  • Postural stability
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18-80 years with clinically diagnosed idiopathic Parkinson's disease;
  • Hoehn and Yahr stage 1-3;
  • Stable antiparkinsonian medication regimen for at least 4 weeks before enrollment;
  • Able to stand unaided and walk independently with or without an assistive device;
  • Adequate corrected vision to perform eye-exercise tasks;
  • Able to understand and follow simple exercise instructions;
  • Able to attend supervised in-center sessions three times per week for 8 weeks;
  • Able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Unstable cardiovascular, orthopedic, vestibular, or neurological condition interfering with safe participation;
  • Active infection or acute medical illness;
  • Severe uncorrected visual impairment preventing participation in eye-exercise tasks;
  • Recent myocardial infarction or stroke within the past 3 months;
  • Change in antiparkinsonian medication during the 4 weeks before enrollment or planned medication change during the intervention period;
  • Severe dizziness, uncontrolled vertigo, or other condition that may be worsened by eye-head coordination exercises;
  • Any other condition judged by the study physician to make participation unsafe.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Supervised In-Center Eye Exercise Group

    Participants will receive a structured eye-exercise program designed to train oculomotor control, gaze stability, and eye-head coordination. The program will be delivered face-to-face in the center during supervised sessions. Each session will last approximately 30 to 45 minutes, 3 sessions per week for 8 weeks.

    Behavioral: Supervised In-Center Eye Exercises

  • No intervention
    Control group

    Participants allocated to the control arm will receive standard neurological care and routine advice to maintain their usual daily activities. They will not receive the structured eye-exercise program during the intervention period.

Interventions

  • BehavioralSupervised In-Center Eye Exercises

    The participants in the study group will perform the eye-exercise program in a standardized seated position under supervision by trained study personnel in a rehabilitation/clinic setting. The exercises will be administered face-to-face and will include progressive visual fixation, smooth pursuit, saccadic eye movements, convergence/divergence, gaze stabilization, and combined eye-head coordination tasks. Progression will be based on increases in movement speed, number of repetitions, task complexity, and participant tolerance, while maintaining the standardized seated position and ensuring safety throughout the intervention.

05

What researchers measure

Primary outcomes

  1. Change in dynamic balance

    Dynamic balance will be assessed using the Mini-BESTest total score. The Mini-BESTest evaluates anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. Higher scores indicate better dynamic balance and postural control.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change in functional mobility

    Assessed with the Timed Up and Go test. Shorter completion times indicate better functional mobility.

    Time frame: Baseline and 8 weeks

  2. Change in gait speed

    Assessed with the 10-Meter Walk Test. Faster walking speed indicates better gait performance.

    Time frame: Baseline and 8 weeks

  3. Change in fall-related concern

    Assessed with the Falls Efficacy Scale-International (FES-I). Higher scores indicate greater concern about falling.

    Time frame: Baseline and 8 weeks

  4. Change in walking endurance

    Assessed with the 6-Minute Walk Test. Greater distance indicates better walking endurance and physical function.

    Time frame: Baseline and 8 weeks

  5. Number of participants with adverse events during the intervention period

    Adverse events will include dizziness, nausea, headache, eye strain, worsening balance, near-falls, falls, musculoskeletal discomfort, or any event requiring session termination or medical evaluation.

    Time frame: Baseline and 8 weeks

06

Study locations

1 site
  • Pardis specialized wellness institute
    Isfahan, Iran
07

References and documents

Publications

  • Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao D, Wang A, Feng T. Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 2024 Jul;5(7):e464-e479. doi: 10.1016/S2666-7568(24)00094-1. PubMed 38945129 ↗
  • Niering M, Wirth C, Beurskens R, Ueding E, Fischer T, Seifert J. Effects of a treadmill and oculomotor dual-task intervention vs. -nordic walking on balance in Parkinson's disease patients - a pilot study. Clin Park Relat Disord. 2025 Sep 8;13:100392. doi: 10.1016/j.prdoa.2025.100392. eCollection 2025. PubMed 41492353 ↗
  • Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JST, Zhang J, Yan R, Zheng X, Wu J, Zhao D, Wang A, Zhou M, Feng T. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025 Mar 5;388:e080952. doi: 10.1136/bmj-2024-080952. PubMed 40044233 ↗
  • Bailo G, Saibene FL, Bandini V, Arcuri P, Salvatore A, Meloni M, Castagna A, Navarro J, Lencioni T, Ferrarin M, Carpinella I. Characterization of Walking in Mild Parkinson's Disease: Reliability, Validity and Discriminant Ability of the Six-Minute Walk Test Instrumented with a Single Inertial Sensor. Sensors (Basel). 2024 Jan 20;24(2):662. doi: 10.3390/s24020662. PubMed 38276354 ↗
  • Culicetto L, Cardile D, Marafioti G, Lo Buono V, Ferraioli F, Massimino S, Di Lorenzo G, Sorbera C, Brigandi A, Vicario CM, Quartarone A, Marino S. Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms. Front Aging Neurosci. 2025 May 21;17:1534073. doi: 10.3389/fnagi.2025.1534073. eCollection 2025. PubMed 40469846 ↗
  • Lorenzo-Garcia P, Cavero-Redondo I, Nunez de Arenas-Arroyo S, Guzman-Pavon MJ, Priego-Jimenez S, Alvarez-Bueno C. Effects of physical exercise interventions on balance, postural stability and general mobility in Parkinson's disease: a network meta-analysis. J Rehabil Med. 2024 Feb 1;56:jrm10329. doi: 10.2340/jrm.v56.10329. PubMed 38298133 ↗
  • Yang Y, Wang G, Zhang S, Wang H, Zhou W, Ren F, Liang H, Wu D, Ji X, Hashimoto M, Wei J. Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis. BMC Geriatr. 2022 Oct 21;22(1):813. doi: 10.1186/s12877-022-03510-9. PubMed 36271367 ↗
  • Waterston JA, Hawken MB, Tanyeri S, Jantti P, Kennard C. Influence of sensory manipulation on postural control in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1993 Dec;56(12):1276-81. doi: 10.1136/jnnp.56.12.1276. PubMed 8270927 ↗
  • Liu WY, Tung TH, Zhang C, Shi L. Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease. Brain Behav. 2022 Aug;12(8):e2690. doi: 10.1002/brb3.2690. Epub 2022 Jul 14. PubMed 35837986 ↗
  • Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2. PubMed 36602886 ↗
  • Mildner S, Hotz I, Kubler F, Rausch L, Stampfer-Kountchev M, Panzl J, Brenneis C, Seebacher B. Effects of activity-oriented physiotherapy with and without eye movement training on dynamic balance, functional mobility, and eye movements in patients with Parkinson's disease: An assessor-blinded randomised controlled pilot trial. PLoS One. 2024 Jun 14;19(6):e0304788. doi: 10.1371/journal.pone.0304788. eCollection 2024. PubMed 38875243 ↗
  • Yang R, Sun M, Chen W, Feng H, Chen B, Liu Y, He Q, Wang L, Zou C, Luo X, Li Z, Fu A, Qiao F, Tang H, Yang J, Ren H. Global, regional and national burden of Parkinson's disease, 1990-2021: Update from the GBD 2021 study. J Neurol Sci. 2026 Jan 15;480:125703. doi: 10.1016/j.jns.2025.125703. Epub 2025 Dec 18. PubMed 41435482 ↗
  • Godi M, Arcolin I, Giardini M, Corna S, Schieppati M. Responsiveness and minimal clinically important difference of the Mini-BESTest in patients with Parkinson's disease. Gait Posture. 2020 Jul;80:14-19. doi: 10.1016/j.gaitpost.2020.05.004. Epub 2020 May 17. PubMed 32464537 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to qualified researchers after publication of the main article.

Supporting information: Sap

08

Registry details

Key details

Study ID
NCT07525973
Lead sponsor
Pardis Specialized Wellness Institute
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
May 1, 2026
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 15, 2026

Study contacts

Mohammad Ali Tabibi, Dr
study director · Pardis Specialized Wellness Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion